Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Sana Biotech­nol­o­gy is prun­ing its pipeline and head­count for the sec­ond time in around a year to stretch its cash and sup­port key da­ta read­outs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.